Ph.I. Spuls
University of Amsterdam
Quality of lifeInternal medicineSurgeryDermatologyRandomized controlled trialIntensive care medicineSystemic therapyPhysical therapyPediatricsAdverse effectAlternative medicinePsoriasis Area and Severity IndexInfliximabEtanerceptAtopic dermatitisMEDLINEAdalimumabPsoriasisSeverity of illnessFamily medicineClinical trialMedicine
140Publications
34H-index
4,303Citations
Publications 148
Newest
#1Satveer K. Mahil (Guy's and St Thomas' NHS Foundation Trust)H-Index: 16
#2Mark Yates ('KCL': King's College London)H-Index: 7
Last. Catherine Smith (Guy's and St Thomas' NHS Foundation Trust)H-Index: 73
view all 43 authors...
OBJECTIVES: Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse COVID-19 outcomes compared to patients receiving no systemic treatments. We used international patient survey data to explore the hypothesis that greater risk-mitigating behaviour in those receiving targeted therapies may account, at least in part, for this observation. METHODS: Online surveys were completed by individuals with psoriasis (globa...
Source
#1Satveer K. Mahil (Guy's and St Thomas' NHS Foundation Trust)H-Index: 16
#2Mark Yates (Guy's and St Thomas' NHS Foundation Trust)H-Index: 7
Last. B. Coker (Guy's and St Thomas' NHS Foundation Trust)H-Index: 2
view all 37 authors...
Indirect excess morbidity in the COVID-19 pandemic may arise from public health risk-mitigation efforts such as stay-at-home orders and re-purposing of healthcare services1 . Increased mental health disorders and shortfalls in the care of long-term conditions are described.
Source
#1Conor Broderick (Guy's and St Thomas' NHS Foundation Trust)H-Index: 2
#2N ChristianH-Index: 1
Last. J L Min (UoB: University of Bristol)H-Index: 1
view all 20 authors...
Dear Editor, BIOMAP (BIOMarkers in Atopic dermatitis and Psoriasis) is a large European consortium aiming to advance personalised medicine for atopic dermatitis and psoriasis by identifying biomarkers which predict therapeutic response and disease progression. BIOMAP brings together clinicians, researchers, patient organisations and pharmaceutical industry partners and encompasses data from over 60 individual studies, including randomised clinical trials, population-based cohorts and deeply-phen...
Source
#1A.L. Bosma (UvA: University of Amsterdam)H-Index: 5
#2L.A.A. Gerbens (UvA: University of Amsterdam)H-Index: 12
Last. Ph.I. Spuls (UvA: University of Amsterdam)H-Index: 34
view all 4 authors...
Dupilumab is a relatively new treatment option for patients with moderate-to-severe atopic dermatitis. There is a lack of knowledge about treatment with dupilumab during conception in both males and females, as well as during pregnancy and lactation. We report four patients who expressed a wish to conceive during treatment with dupilumab in daily practice. Two male patients conceived during dupilumab treatment, and two female patients discontinued dupilumab because of anticipated pregnancy. Apar...
Source
Since the introduction of active vaccination against SARS-CoV-2 infection, there has been a debate about the risk of developing severe allergic or anaphylactic reactions among individuals with a history of allergy. Indeed, rare cases of severe allergic reactions have been reported in the United Kingdom and North America. By february 2021 a rate of 4,5 severe allergic reactions occurred among 1 million patients vaccinated with the mRNA-based COVID-19 vaccines, which is higher than the generally e...
Source
#1Ginger B. Langbroek (UvA: University of Amsterdam)H-Index: 2
#2A. Wolkerstorfer (UvA: University of Amsterdam)H-Index: 7
Last. Dirk T. Ubbink (UvA: University of Amsterdam)H-Index: 54
view all 17 authors...
BACKGROUND Due to a large variety in treatment outcomes reported in therapeutic trials and lacking patient-relevant outcomes, it is hard to adequately compare and improve current therapies for patients with capillary malformations (CMs). The Core Outcome Set for Capillary Malformations (COSCAM) project aims to develop a core outcome set (COS) for use in future CM trials, in which we will first develop a core outcome (sub)domain set (CDS). Here we describe the methods for the development of a CDS...
Source
#1L. Howells (University of Nottingham)H-Index: 7
#2S. Gran (University of Nottingham)H-Index: 4
Last. Kim S Thomas (University of Nottingham)H-Index: 34
view all 13 authors...
Source
#1A.C. Fledderus (UvA: University of Amsterdam)H-Index: 3
#2Suzanne G.M.A. Pasmans (EUR: Erasmus University Rotterdam)H-Index: 30
Last. Ph.I. Spuls (UvA: University of Amsterdam)H-Index: 34
view all 8 authors...
BACKGROUND Congenital melanocytic naevi (CMN) can have a great impact on patients' lives due to perceived stigmatization and the risk of melanoma development and neurological complications. Development of a core outcome set for care and research of CMN will allow standard reporting of outcomes. This will enable comparison of outcomes, allowing professionals to offer advice about best management options. In previous research, stakeholders (patients, parents, and professionals) reached consensus o...
Source
#1M.M. Lokhorst (UvA: University of Amsterdam)H-Index: 4
#2Ser Horbach (UvA: University of Amsterdam)H-Index: 1
Last. Laurence M. BoonH-Index: 54
view all 7 authors...
BACKGROUND The symptoms and appearance of vascular malformations can severely harm a patient's quality of life. The aim of treatment of vascular malformations generally is to improve condition-specific symptoms and/or appearance. Therefore, it is highly important to start testing treatment effects in clinical studies from the patient's perspective. OBJECTIVES The objective of this study was to develop a patient-reported outcome measure (PROM) for measuring symptoms and appearance in patients wit...
Source
The coronavirus disease 2019 (COVID-19) pandemic is caused by rapid spread of different strains of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The severity of infection ranges from mild, or even asymptomatic, to very severe. Signs and symptoms include fatigue, fever, exanthemas, upper respiratory illness, loss of smell and taste, pneumonia, severe acute respiratory syndrome, and multi-organ failure. Risk factors for a severe or lethal course include age, male gender, obesit...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.